- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Treatment of Demodex Blepharitis
An overview of the current landscape of available treatment options for Demodex blepharitis is analyzed.
EP: 1.Overview of Demodex Blepharitis
EP: 2.Pathophysiology of Demodex Blepharitis
EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice
EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis
EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis
EP: 6.Treatment of Demodex Blepharitis
EP: 7.Diagnosis and Prevalence of Demodex Blepharitis
EP: 8.Exploring a Recently Approved Therapy for Demodex
EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis
EP: 10.Outlook on the Future of Demodex Blepharitis Treatment
EP: 11.Understanding Demodex Blepharitis Pathogenesis
EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment
EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment
This is a video synopsis/summary of a discussion involving Elizabeth Yeu, MD.
Yeu discusses how the recent FDA approval of lotilaner ophthalmic solution 0.25% (Xdemvy) finally provides an effective treatment for patients with Demodex blepharitis. Unlike past therapies, this clear solution dosed twice daily has superb efficacy alongside excellent safety and tolerability. In two combined studies, 50% of patients had a reduction of collarettes and 60% of patients had mites completely eradicated. Such substantial improvement was unprecedented. Additionally, the solution form is preferable to a blurring ointment that is hard to apply. Yeu is excited to have an excellent therapeutic option now. She can educate and empower patients about this new treatment, targeting the root cause of their condition.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More
